[18F]-JK-PSMA-7 在 prostate cancer PET/CT 中的生物分布与辐射剂量学
本研究纳入 10 例生化复发或影像学转移的前列腺癌患者,注射 329-384 MBq(均值 359 ± 17 MBq)[18F]-JK-PSMA-7 后行 8 次序贯 PET 扫描。全身有效剂量为 1.09E-02 mGy/MBq,肾脏吸收剂量最高(1.76E-01 mGy/MBq)。PSMA 阳性病灶 SUVmax 和 SUVpeak 在注射后 60 分钟上升并维持至 140 分钟,170-200 分钟进一步显著升高,提示 PET/CT 采集应尽可能延迟。
要点
- 全身有效剂量为 1.09E-02 mGy/MBq,肾脏吸收剂量最高(1.76E-01 mGy/MBq)。
- PSMA 阳性病灶 SUVmax 和 SUVpeak 在注射后 170-200 分钟进一步显著升高,TBR 最高见于 3 小时。
- 生理性摄取见于唾液腺、泪腺、肝、脾和肠道,排泄经泌尿和胆道途径。
核心结论
- [18F]-JK-PSMA-7 的最高肿瘤-本底比(TBR)见于注射后 3 小时,PET/CT 采集开始时间应尽可能延迟。
研究设计与样本
- 纳入 10 例前列腺癌伴生化复发或影像学转移证据的患者,注射 329-384 MBq(均值 359 ± 17 MBq)[18F]-JK-PSMA-7 后行 8 次序贯 PET 扫描(20 分钟至 3 小时)。
主要发现
- 全身有效剂量为 1.09E-02 mGy/MBq。
- 肾脏吸收剂量最高(1.76E-01 mGy/MBq),其次为肝脏(7.61E-02 mGy/MBq)、唾液腺(4.68E-02 mGy/MBq)、脾(1.89E-02 mGy/MBq)和肺(1.10E-2 mGy/MBq)。
- 10 例中 6 例评为 PSMA 阳性,共分析 18 个可疑病灶(骨 6、淋巴结 9、前列腺窝局部 3)。
- PSMA 阳性病灶 SUVmax 和 SUVpeak 在注射后 60 分钟上升并维持至 140 分钟,170-200 分钟进一步显著升高。
- 未观察到示踪剂注射的不良反应。
关键数值与推荐
- 全身有效剂量 1.09E-02 mGy/MBq。
- 肾脏吸收剂量 1.76E-01 mGy/MBq,肝脏 7.61E-02 mGy/MBq,唾液腺 4.68E-02 mGy/MBq,脾 1.89E-02 mGy/MBq,肺 1.10E-2 mGy/MBq。
- PSMA 阳性病灶 SUVmax 和 SUVpeak 在注射后 170-200 分钟进一步显著升高,TBR 最高见于 3 小时。
临床怎么用
- 基于动力学数据,[18F]-JK-PSMA-7 PET/CT 采集开始时间应尽可能延迟,以获取最高 TBR。
- 可疑病灶绝对 SUVmax 和相对 TBR 较高,提示该示踪剂对前列腺癌病灶检测可能具有较高敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a novel 18F-labeled PSMA-ligand for PET/CT imaging of prostate cancer. METHODS: Ten patients with prostate cancer and biochemical recurrence or radiologic evidence of metastatic diseases were examined with 329-384 MBq (mean 359 ± 17 MBq) [18F]-JK-PSMA-7. Eight sequential positron emission tomography (PET) scans were acquired from 20 min to 3 h after injection with IRB approval. The kidneys, liver, lungs, spleen, and salivary glands were segmented into volumes of interest using the QDOSE dosimetry software suite (ABX-CRO, Germany). Absorbed and effective dose were calculated using the ICRP-endorsed IDAC 1.0 package. The absorbed dose of the salivary glands was determined using the spherical model of OLINDA 1.1. PSMA-positive lesions were evaluated separately. Quantitative assessment of the uptake in suspicious lesions was performed by analysis of maximum (max) and peak SUV values. The gluteus maximus muscle (SUVmean) served as a reference region for the calculation of tumor-to-background ratios (TBR's). RESULTS: Physiologic radiotracer accumulation was observed in the salivary and lacrimal glands, liver, spleen, and intestines, in a pattern resembling the distribution known from other PSMA-tracers with excretion via urinary and biliary pathways. The effective dose from [18F]-JK-PSMA-7 for the whole body was calculated to be 1.09E-02 mGy/MBq. The highest radiation dose was observed in the kidneys (1.76E-01 mGy/MBq), followed by liver (7.61E-02 mGy/MBq), salivary glands (4.68E-02 mGy/MBq), spleen (1.89E-02 mGy/MBq), and lungs (1.10E-2 mGy/MBq). No adverse effects of tracer injection were observed. Six out of ten patients were scored as PSMA-positive. A total of 18 suspicious lesions were analyzed, which included six bone lesions, nine lymph nodes, and three local lesions within the prostate fossa. The values for the SUVmax and SUVpeak in the PSMA-positive lesions increased until 60 min p.i. and remained at this intensity in the PET/CT scans until 140 min. In the period between 170 and 200 min after injection, a further significant increase in SUVmax and SUVpeak within the PSMA-positive lesions was observed. CONCLUSIONS: The highest TBR of [18F]-JK-PSMA-7 was found 3 h after injection. From the kinetically collected data, it can be concluded that this trend may also continue in the further course. The start of the PET/CT acquisition should be chosen as late as possible. The high uptake in suspicious lesions in terms of absolute SUVmax and relative TBR values indicates potentially high sensitivity of the tracer for detection of prostate cancer manifestations.
引用
- Hohberg M, Kobe C, Krapf P, et al. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019. PMID: 31346821. doi:10.1186/s13550-019-0540-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。